Debiopharm Competitors and Similar CompaniesClear all
Debiopharm's competitors and similar companies include TriSalus Life Sciences, Sunshine Biopharma, Turning Point Therapeutics and Pyxis Oncology.
 Debiopharm Debiopharm is a biopharmaceutical company specializing in oncology and bacterial infections. |  TriSalus Life Sciences TriSalus Life Sciences (formerly MedTech Acquisition and Surefire Medical) is a company that develops a transformative platform for treating liver and pancreatic tumors. |  Sunshine Biopharma Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer. |  Turning Point Therapeutics Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases. |  Pyxis Oncology Pyxis Oncology is a preclinical oncology company focused on developing therapeutics to target difficult-to-treat cancers. | |
Founding Date | Founding Date 1979 | Founding Date 2009 | Founding Date 2006 | Founding Date 2013 | Founding Date 2019 |
Type | Type Private | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Lausanne, CH HQ Oss, NL | Locations Westminster, US HQ Bannockburn, US Cranston, US | Locations Pointe-Claire, CA HQ | Locations San Diego, US HQ | Locations Cambridge, US HQ |
Employees | Employees 4771% decrease | Employees 106 | Employees 5218% increase | Employees 474% decrease | Employees 39 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 117.2 m | Valuation ($) 5.8 m | Valuation ($) N/A | Valuation ($) 227 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $45.2m (FY, 2025) | Revenue (est.) $36.3m (FY, 2025) | Revenue (est.) $30.8m (FY, 2021) | Revenue (est.) $13.9m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $7m (FY, 2025) | Cost of goods $24.1m (FY, 2025) | Cost of goods N/A | Cost of goods $2.4m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $38.2m (FY, 2025) | Gross profit $12.3m (FY, 2025) | Gross profit N/A | Gross profit $11.5m (FY, 2025) |
Net income | Net income N/A | Net income ($39.2m) (FY, 2025) | Net income ($6m) (FY, 2025) | Net income ($236.6m) (FY, 2021) | Net income ($79.6m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 2.1m | Total funding raised $ 52.2m | Total funding raised N/A | Total funding raised $ 144.4m | Total funding raised $ 174m |
For sources of this data, please see the company profile
View Company Profiles
TriSalus Life Sciences
HQ
Westminster, US
Employees
106
TriSalus Life Sciences (formerly MedTech Acquisition and Surefire Medical) is a company that develops a transformative platform for treating liver and pancreatic tumors.
View companySunshine Biopharma
HQ
Pointe-Claire, CA
Employees
52↑ 18% increase
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
View companyTurning Point Therapeutics
HQ
San Diego, US
Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases.
View companyPyxis Oncology
HQ
Cambridge, US
Employees
39
Pyxis Oncology is a preclinical oncology company focused on developing therapeutics to target difficult-to-treat cancers.
View company